Targeted lipid nanoparticles containing IL-10 mRNA improve outcomes in experimental intracerebral hemorrhage

Oct 15, 2025Journal of neuroinflammation

Lipid nanoparticles carrying IL-10 mRNA may improve recovery after brain hemorrhage

AI simplified

mRNA Technology on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

Treatment with - containing IL-10 mRNA led to a 69% reduction in hematoma size at 72 hours in an experimental mouse model of .

Inflammation is a key mechanism contributing to secondary damage after intracerebral hemorrhage (ICH).
Targeting the inflamed endothelium in the brain could improve therapeutic strategies for ICH.
Lipid nanoparticles (LNPs) conjugated with antibodies against vascular cellular adhesion molecule (VCAM) demonstrated enhanced delivery to the inflamed brain.
VCAM-LNPs distributed to the brain approximately 4 times more than nonspecific LNPs and delivered their cargo at 10 times higher levels.
Motor behavior improved by about 65% following treatment with VCAM-LNPs containing IL-10 mRNA.
The therapeutic benefit may involve modulation of brain macrophage phenotype.

AI simplified

(ICH) is a lethal and highly morbid form of stroke for which there is no disease-specific therapy. Inflammation after ICH is an important mechanism of secondary damage, and the inflamed endothelium in ICH is a promising therapeutic target as it is the gateway for recruitment of peripheral inflammatory cells to the brain. Systemic therapies that target inflammation have been unsuccessful in stroke, in part due to side effects or poor brain delivery. We hypothesized that targeting mRNA encoding IL-10, a potent anti-inflammatory cytokine, to the brain vasculature would improve outcomes in an experimental mouse model of ICH. We manufactured (LNPs) using microfluidics, packaged them with IL-10 mRNA, and conjugated them with antibodies against vascular cellular adhesion molecule (), which can bind the inflamed brain endothelium after ICH. VCAM LNPs distributed to the brain ~ 4x more than nonspecific LNPs and expressed their cargo in the brain at 10x higher levels. Treatment with VCAM-LNPs containing IL-10 mRNA led to ~ 69% reduction in hematoma size at 72 h by histology and decreased lesion size in MRI, and ~ 65% improvement in motor behavior in our model. Finally, we propose that VCAM-IL10-LNPs enact their therapeutic benefit via modulation of brain macrophage phenotype. Our data bring forth a promising therapeutic and delivery strategy for ICH, and shed light on the effects of acute targeting of inflammation in ICH lesion size and behavior. Future experiments will seek to understand how serial dosing affects LNP expression in our model and whether treatment at later time points after ICH can still confer therapeutic effects.

Key numbers

10×

Increase in mRNA Expression

express mRNA in the brain at levels compared to non-specific .

69%

Reduction in Size

size decreased at 72 hours post-treatment with -IL10-.

65%

Improvement in Motor Behavior

Motor behavior improved in mice treated with -IL10-.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text (PDF) ↗View full text (HTML) ↗

Targeted lipid nanoparticles containing IL-10 mRNA improve outcomes in experimental intracerebral hemorrhage

Abstract

Key numbers

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief

Abstract

Key numbers

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief